How should I manage a patient with a left ventricular ejection fraction of 20%?

Management of Left Ventricular Ejection Fraction 20%

Immediately initiate quadruple guideline-directed medical therapy (ACE-inhibitor or ARNI, beta-blocker, mineralocorticoid receptor antagonist, and SGLT2-inhibitor) at low doses with parallel uptitration every 1–2 weeks, and simultaneously evaluate for ICD and cardiac resynchronization therapy, because an ejection fraction of 20% places this patient in the highest-risk category where each week of delay reduces the opportunity for reverse remodeling and increases mortality risk. 1

Immediate Pharmacologic Therapy

• Start all four core drug classes simultaneously rather than sequentially, because early initiation of the complete regimen (within ≈2 months of LV dysfunction onset) yields a ≈73% relative reduction in 2-year mortality compared with no treatment. 1

• ACE-inhibitor or ARNI: Begin with low-dose ACE-inhibitor (e.g., enalapril 2.5 mg twice daily) and uptitrate to target doses (enalapril 10–20 mg twice daily). 2, 1 If the patient tolerates ACE-inhibitor therapy and remains symptomatic, consider switching to sacubitril/valsartan (ARNI), which demonstrated an 11% reduction in all-cause mortality and 30% reduction in heart failure hospitalization compared to enalapril in patients with LVEF ≤40%. 3

• Beta-blocker: Initiate evidence-based beta-blockers (carvedilol, metoprolol succinate, or bisoprolol) once the patient is euvolemic and stable on ACE-inhibitor therapy, targeting carvedilol 25 mg twice daily, metoprolol succinate 200 mg daily, or bisoprolol 10 mg daily. 2, 1, 4

• Mineralocorticoid receptor antagonist: Add spironolactone 25 mg daily for patients with NYHA class III–IV symptoms to reduce mortality and sudden death. 2, 1

• SGLT2-inhibitor: Initiate an SGLT2-inhibitor with proven cardiovascular benefit to reduce cardiovascular events, independent of diabetes status. 1

• Loop diuretics: Start furosemide 20–40 mg daily promptly to achieve rapid relief of pulmonary congestion and peripheral edema in symptomatic patients. 2

Device Therapy Evaluation

Implantable Cardioverter-Defibrillator (ICD)

• ICD implantation is a Class I, Level A recommendation for patients with LVEF ≤35% (which includes your patient with 20% EF) who have reasonable expectation of meaningful survival for >1 year. 1, 4

• For ischemic cardiomyopathy: ICD is indicated when the patient is at least 40 days post-myocardial infarction with NYHA class II–III symptoms on optimal medical therapy. 1, 4

• For non-ischemic cardiomyopathy: ICD is indicated for patients with LVEF ≤30% (which includes 20%) and NYHA class I symptoms, or LVEF ≤35% with NYHA class II–III symptoms. 1, 4

• The benefit of ICD increases as ejection fraction decreases below 35%, with patients having EF <30% showing larger mortality reductions (HR 0.72) compared to those with EF 30–35% (HR 0.83). 4

Cardiac Resynchronization Therapy (CRT)

• CRT is a Class I, Level A recommendation for patients with LVEF ≤35%, sinus rhythm, left bundle branch block (LBBB) with QRS duration ≥150 ms, and NYHA class II–IV symptoms on guideline-directed medical therapy. 1, 4

• CRT reduces all-cause mortality, heart failure hospitalizations, and improves symptoms and quality of life in this population. 1

• For non-LBBB morphology with QRS ≥150 ms, CRT is Class IIa, Level A. 1

• For QRS duration 120–149 ms: LBBB morphology is Class IIa, Level A; non-LBBB is Class IIb, Level A. 1

• In atrial fibrillation patients, CRT is beneficial (Class IIa, Level A) if near-100% biventricular pacing can be achieved (typically ≥90–95%), which may require AV junction ablation if pharmacologic rate control fails. 1, 4

• Do not implant CRT when QRS duration is <120 ms (Class III, Level A—harmful). 1

Revascularization Considerations

• A multidisciplinary Heart Team should evaluate coronary anatomy, the correlation between coronary artery disease and LV dysfunction, comorbidities, life expectancy, individual risk-benefit ratio, and patient preferences to decide between revascularization and optimal medical therapy. 5, 1, 4

• In surgically eligible patients with multivessel coronary artery disease and LVEF ≤35%, coronary artery bypass grafting (CABG) is recommended over medical therapy alone to improve long-term survival (Class I, Level B). 5, 1, 4

• CABG provides greater benefit than medical therapy alone when viable myocardium is present in the target vascular territory, which should be assessed by stress imaging or PET when available. 1

• Use fractional-flow reserve (FFR) or instantaneous wave-free ratio (iFR) to guide lesion selection for intervention in patients with multivessel disease. 5, 1

• For patients at high surgical risk, PCI may be considered as an alternative to CABG (Class IIb, Level B). 5, 1

Valvular Considerations

• Assess for functional (secondary) mitral regurgitation, which occurs commonly in patients with LVEF 20% due to left ventricular dilatation causing annular enlargement and papillary-muscle displacement. 1

• If severe secondary mitral regurgitation is present and the patient remains symptomatic despite optimal guideline-directed medical therapy, mitral valve surgery (repair or replacement) is reasonable. 5

• Mitral valve surgery is also reasonable when coronary artery bypass graft (CABG) is indicated in patients with severe secondary MR. 5

Risk Stratification and Prognosis

• An ejection fraction of 20% signifies exhausted preload reserve and inadequate hypertrophic compensatory mechanisms to sustain cardiac output, representing decompensated heart failure. 1, 4

• Patients with LVEF ≤35% have a high risk of sudden cardiac death, progressive pump failure, and arrhythmic complications, underscoring the need for early aggressive therapy. 1

• Prolonged severe LV dysfunction leads to progressive chamber dilatation, adverse remodeling, and irreversible myocardial fibrosis if left untreated, but early guideline-directed intervention can partially reverse systolic dysfunction at this level. 1

• Chronic elevation of LV filling pressures produces pulmonary venous hypertension that progresses to irreversible pulmonary vascular remodeling, contributing to right-heart failure. 1

• Severe LV dysfunction with akinetic or dyskinetic segments creates stagnant intracavitary flow, predisposing to left-ventricular thrombus formation and embolic risk. 1

Common Pitfalls to Avoid

• Do not delay device therapy evaluation while attempting to optimize medical therapy alone—these interventions should proceed in parallel for eligible patients. 4

• Do not use non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with EF ≤35%, as they have negative inotropic effects and may worsen outcomes. 1, 4

• Do not allow LVEF to fall into the lower limit of normal range before intervening—unlike aortic regurgitation, heart failure management requires action at higher EF thresholds. 5

• Do not implant ICD or CRT when anticipated life expectancy is <1 year due to severe comorbidities or frailty. 1

• Avoid nonsteroidal anti-inflammatory drugs, most antiarrhythmic drugs, and calcium channel blockers, as they should be withdrawn or avoided in this population. 6

Rehabilitation and Lifestyle

• Enroll stable patients in a supervised, group-based cardiac rehabilitation program that includes exercise, psychological support, and education, as moderate-quality evidence shows this reduces hospital admissions and improves long-term quality of life. 2

• Advise patients with severe heart failure to limit dietary sodium and restrict excess fluid intake as part of standard self-care measures. 2

• Counsel patients to avoid excessive alcohol consumption and to refrain from smoking to mitigate additional cardiovascular risk. 2